{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:33:17Z","timestamp":1767598397352,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"crossref","award":["16H05451","17H01540"],"award-info":[{"award-number":["16H05451","17H01540"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"crossref","award":["2018-Kenkyu-Shorei"],"award-info":[{"award-number":["2018-Kenkyu-Shorei"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ono Cancer Research Fund","award":["2017-3"],"award-info":[{"award-number":["2017-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00262-019-02455-0","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T15:02:42Z","timestamp":1576681362000},"page":"189-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3678-4359","authenticated-orcid":false,"given":"Tomohide","family":"Tsukahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazue","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akari","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Kameshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Hatae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rituko","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Murai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehide","family":"Nakatsugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terufumi","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Kanaseki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Hirohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Terui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Asanuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Torigoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,18]]},"reference":[{"key":"2455_CR1","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/14712598.2016.1188075","volume":"16","author":"T Tsukahara","year":"2016","unstructured":"Tsukahara T, Emori M, Murata K, Mizushima E, Shibayama Y, Kubo T, Kanaseki T, Hirohashi Y, Yamashita T, Sato N, Torigoe T (2016) The future of immunotherapy for sarcoma. Expert Opin Biol Ther 16:1049\u20131057","journal-title":"Expert Opin Biol Ther"},{"key":"2455_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/pin.12438","volume":"66","author":"T Tsukahara","year":"2016","unstructured":"Tsukahara T, Hirohashi Y, Kanaseki T, Nakatsugawa M, Kubo T, Sato N, Torigoe T (2016) Peptide vaccination therapy: towards the next generation. Pathol Int 66:547\u2013553","journal-title":"Pathol Int"},{"key":"2455_CR3","first-page":"1731","volume":"8","author":"Y Hirohashi","year":"2002","unstructured":"Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N (2002) An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 8:1731\u20131739","journal-title":"Clin Cancer Res"},{"key":"2455_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1349-7006.2008.00695.x","volume":"99","author":"T Tsukahara","year":"2008","unstructured":"Tsukahara T, Kawaguchi S, Torigoe T, Kimura S, Murase M, Ichimiya S, Wada T, Kaya M, Nagoya S, Ishii T, Tatezaki S, Yamashita T, Sato N (2008) Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma. Cancer Sci 99:368\u2013375","journal-title":"Cancer Sci"},{"key":"2455_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/cas.13854","volume":"110","author":"K Watanabe","year":"2019","unstructured":"Watanabe K, Tsukahara T, Toji S, Saitoh S, Hirohashi Y, Nakatsugawa M, Kubo T, Kanaseki T, Kameshima H, Terui T, Sato N, Torigoe T (2019) Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells. Cancer Sci 110:40\u201351","journal-title":"Cancer Sci"},{"key":"2455_CR6","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1158\/0008-5472.CAN-04-0522","volume":"64","author":"T Tsukahara","year":"2004","unstructured":"Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, Ida K, Asanuma H, Hirohashi Y, Torigoe T, Hiraga H, Nagoya S, Wada T, Yamashita T, Sato N (2004) Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 64:5442\u20135448","journal-title":"Cancer Res"},{"key":"2455_CR7","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2006.00317.x","volume":"97","author":"T Tsukahara","year":"2006","unstructured":"Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T, Yamashita T, Sato N (2006) Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 97:1374\u20131380","journal-title":"Cancer Sci"},{"issue":"4","key":"2455_CR8","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/cas.13969","volume":"110","author":"Kuniko Sunami","year":"2019","unstructured":"Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T (2019) Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci 110. https:\/\/doi.org\/10.1111\/cas.13969","journal-title":"Cancer Science"},{"key":"2455_CR9","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pag\u00e8s F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39:782\u2013795","journal-title":"Immunity"},{"key":"2455_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.12314","volume":"105","author":"Y Komohara","year":"2014","unstructured":"Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105:1\u20138","journal-title":"Cancer Sci"},{"key":"2455_CR11","doi-asserted-by":"publisher","first-page":"168145","DOI":"10.1155\/2013\/168145","volume":"2013","author":"RG Maki","year":"2013","unstructured":"Maki RG, Jungbluth AA, Gnjatic S, Schwartz GK, D\u2019Adamo DR, Keohan ML, Wagner MJ, Scheu K, Chiu R, Ritter E, Kachel J, Lowy I, Old LJ, Ritter G (2013) A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013:168145","journal-title":"Sarcoma"},{"key":"2455_CR12","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D\u2019Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18:1493\u20131501","journal-title":"Lancet Oncol"},{"key":"2455_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40425-017-0301-y","volume":"5","author":"R Groisberg","year":"2017","unstructured":"Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V (2017) Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 5:100","journal-title":"J Immunother Cancer"},{"key":"2455_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416\u2013426","journal-title":"Lancet Oncol"},{"key":"2455_CR15","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1002\/cncr.30726","volume":"123","author":"SM Pollack","year":"2017","unstructured":"Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL (2017) T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer 123:3291\u20133304","journal-title":"Cancer"},{"key":"2455_CR16","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/cas.13319","volume":"108","author":"Y Shibayama","year":"2017","unstructured":"Shibayama Y, Tsukahara T, Emori M, Murata K, Mizushima E, Hirohashi Y, Kanaseki T, Nakatsugawa M, Kubo T, Yamashita T, Sato N, Torigoe T (2017) Implication of chemo-resistant memory T cells for immune surveillance in patients with sarcoma receiving chemotherapy. Cancer Sci 108:1739\u20131745","journal-title":"Cancer Sci"},{"key":"2455_CR17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev.immunol.21.120601.141036","volume":"21","author":"PA van der Merwe","year":"2003","unstructured":"van der Merwe PA, Davis SJ (2003) Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 21:659\u2013684","journal-title":"Annu Rev Immunol"},{"key":"2455_CR18","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00262-018-2217-x","volume":"67","author":"H Shima","year":"2018","unstructured":"Shima H, Kutomi G, Satomi F, Imamura M, Kimura Y, Mizuguchi T, Watanabe K, Takahashi A, Murai A, Tsukahara T, Kanaseki T, Hirohashi Y, Iwayama Y, Tsuruma T, Kameshima H, Sato N, Torigoe T, Takemasa I (2018) Case report: long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine. Cancer Immunol Immunother 67:1603\u20131609","journal-title":"Cancer Immunol Immunother"},{"key":"2455_CR19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","volume":"21","author":"GT Gibney","year":"2015","unstructured":"Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS (2015) Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 21:712\u2013720","journal-title":"Clin Cancer Res"},{"key":"2455_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","volume":"5","author":"E Massarelli","year":"2019","unstructured":"Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, Haymaker C, Bernatchez C, Curran M, Zecchini Barrese T, Rodriguez Canales J, Wistuba I, Li L, Wang J, van der Burg SH, Melief CJ, Glisson B (2019) Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16\u2013related cancer. JAMA Oncol 5:67\u201373","journal-title":"JAMA Oncol"},{"key":"2455_CR21","doi-asserted-by":"publisher","first-page":"e1165376","DOI":"10.1080\/2162402X.2016.1165376","volume":"5","author":"K Murata","year":"2016","unstructured":"Murata K, Tsukahara T, Emori M, Shibayama Y, Mizushima E, Matsumiya H, Yamashita K, Kaya M, Hirohashi Y, Kanaseki T, Kubo T, Himi T, Ichimiya S, Yamashita T, Sato N, Torigoe T (2016) Identification of a novel human memory T-cell population with the characteristics of stem-like chemo-resistance. Oncoimmunology 5:e1165376","journal-title":"Oncoimmunology"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02455-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02455-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02455-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:08:36Z","timestamp":1608163716000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02455-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2455"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02455-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2019,12,18]]},"assertion":[{"value":"21 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Tomohide Tsukahara, Yoshihiko Hirohashi, Takayuki Kanaseki, Munehide Nakatsugawa, Terufumi Kubo, and Toshihiko Torigoe received financial support through collaboration with Ono Pharmaceutical Co., Ltd. Tomohide Tsukahara, Yoshihiko Hirohashi, Takayuki Kanaseki, and Toshihiko Torigoe received financial support through collaboration with Medical Biological Laboratories Co., Ltd. The authors declare that there are no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the guidelines established by the Declaration of Helsinki and approved by the Ethics Committees of Higashi-Sapporo Hospital (260630) and Sapporo Medical University (282-156).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"The patient and his family provided written informed consent for the use of tumor and blood samples in our research and for publication. Blood from healthy donors was collected by the Japanese Red Cross Hokkaido Block Blood Center after obtaining informed consent from the donors for research purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"C1R-A24 cells (C1R cells transfected with HLA-A*24:02 cDNA) were kindly provided by Dr. M. Takiguchi (Kumamoto University School of Medicine, Japan). C1R-A24 cells were authenticated by HLA typing.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}